ERLEADA® + ADT demonstrates a consistent, acceptable safety profile[1]

The median follow-up time in the TITAN final analysis was 44 months.[1] The most common reason for discontinuation was progressive disease.[1]

The safety profile of ERLEADA® + ADT remained consistent with that reported previously, with no new safety signals detected.[1]

Dr helps patient at home
Incidence of TEAEs (N=1051)[2]
TEAEs of interest[1]
Cumulative incidences[2]
AE, n (%)a
ERLEADA® + ADT (n=524)
Placebo + ADT (n=527)
Crossover (placebo to ERLEADA®) + ADT (n=208)

Patients with ≥1 TEAEb

510 (97.3)

510 (96.8)

174 (83.7)

Patients with ≥1 grade 3/4 TEAE

259 (49.4)

220 (41.7)

57 (27.4)

Any serious TEAEb
153 (29.2)

115 (21.8)

29 (13.9)

Any TEAE leading to treatment discontinuation

62 (11.8)

30 (5.7)

16 (7.7)

TEAE leading to death

20 (3.8)

17 (3.2)

7 (3.4)
3 (1.4)

Adapted from Chi KN, et al. 2021 (supplementary).

Treat early and push back on progression with the consistent safety profile demonstrated with ERLEADA® + ADT[1]

Click below to find out more about the clinical benefits with ERLEADA®+ ADT

Increase survival and delay progression

Treat early with ERLEADA® + ADT to delay progression and extend life for your mHSPC patients vs. placebo + ADT[1]

Treat early in a broad range of mHSPC patients

Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[1]

Maintain QoL

Push back on progression and maintain QoL in mHSPC[1]


ADT, androgen deprivation therapy. AE, adverse event. mHSPC, metastatic hormone-sensitive prostate cancer. PY, patient-years. QoL, quality of life. TEAE, treatment-emergent adverse event


Chi KN, et al. J Clin Oncol 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
Chi KN, et al. J Clin Oncol 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488 (supplementary).
CP-282954 - January 2022